These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11368429)

  • 1. Prospect for immunotherapy of acute lymphoblastic leukemia.
    Velders MP; ter Horst SA; Kast WM
    Leukemia; 2001 May; 15(5):701-6. PubMed ID: 11368429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in pediatric B-cell acute lymphoblastic leukemia.
    Wyatt KD; Bram RJ
    Hum Immunol; 2019 Jun; 80(6):400-408. PubMed ID: 30716352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
    Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
    Front Immunol; 2018; 9():239. PubMed ID: 29515572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.
    Ruella M; Gill S
    Expert Opin Biol Ther; 2015 Jun; 15(6):761-6. PubMed ID: 25640460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
    Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
    Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Therapies in Acute Lymphoblastic Leukemia.
    Phelan KW; Advani AS
    Curr Hematol Malig Rep; 2018 Aug; 13(4):289-299. PubMed ID: 30078158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia.
    Turazzi N; Fazio G; Rossi V; Rolink A; Cazzaniga G; Biondi A; Magnani CF; Biagi E
    Br J Haematol; 2018 Sep; 182(6):939-943. PubMed ID: 28832950
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential use of CD40 ligand for immunotherapy of childhood B-cell precursor acute lymphoblastic leukaemia.
    D'Amico G; Marin V; Biondi A; Bonamino MH
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):465-77. PubMed ID: 15498717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies and immune therapies for adult precursor B-acute lymphoblastic leukemia.
    Sikaria S; Aldoss I; Akhtari M
    Immunol Lett; 2016 Apr; 172():113-23. PubMed ID: 26921100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
    Advani A
    Best Pract Res Clin Haematol; 2015; 28(2-3):116-23. PubMed ID: 26590768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.
    Kebriaei P; Poon ML
    Curr Hematol Malig Rep; 2015 Jun; 10(2):76-85. PubMed ID: 25899862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances of treatment study on acute lymphoblastic leukemia with chimeric antigen receptor modified T cells].
    Weng WW; Tang YM
    Zhonghua Er Ke Za Zhi; 2019 Aug; 57(8):643-646. PubMed ID: 31352754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.
    Haining WN; Cardoso AA; Keczkemethy HL; Fleming M; Neuberg D; DeAngelo DJ; Stone RM; Galinsky I; Silverman LB; Sallan SE; Nadler LM; Guinan EC
    Exp Hematol; 2005 Mar; 33(3):286-94. PubMed ID: 15730852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T-cells for relapsed B-cell ALL in adults.
    Gilbert JA
    Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
    [No Abstract]   [Full Text] [Related]  

  • 17. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
    Wang M
    Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
    [No Abstract]   [Full Text] [Related]  

  • 18. TSLPR: a new CAR in the showroom for B-ALL.
    Davies DM; Maher J
    Blood; 2015 Jul; 126(5):567-9. PubMed ID: 26228169
    [No Abstract]   [Full Text] [Related]  

  • 19. BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia.
    Amro Elshoury ; Wallace PK; Borowitz MJ; Kader A; Choi C; Ho C; Balderman S; Ross M; Hahn T; O'Neill V; McCarthy PL; Chen GL
    Bone Marrow Transplant; 2018 May; 53(5):651-653. PubMed ID: 29343836
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances.
    Vrooman LM; Silverman LB
    Curr Hematol Malig Rep; 2016 Oct; 11(5):385-94. PubMed ID: 27502091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.